Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, spoke about her health plan’s requirements on quality measures and whether they resonate what CMS requires providers to submit.
Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, spoke about her health plan’s requirements on quality measures and whether they resonate what CMS requires providers to submit.
“What we have been focusing on and reports that we’re going to be providing to practices include adherence to our pathways as well as [emergency department] utilization and hospitalizations during treatment and access to hospice and other end-of-life care,” Dr Malin said. She added that these measures are a part of what CMS requires through the Oncology Care Model.
However, for Dr Malin, she sees challenges with developing a small set of more meaningful measures that can be used across their entire network. The crux is to derive maximum information without placing further burden on the practices. She said that Anthem has been working to find a “sweet spot of measures” to help practices compare themselves with other practices across the health plan’s network.
Dr Malin said that America’s Health Insurance Plans, or AHIP, has a work group that has brought together private payers and CMS, which “led to the short list of measures that's included in the current oncology care model.” The challenge, however, remains the lack of standardization across practices, with respect to the data systems used. She went on to add that with pay-for-performance and accountability, the National Quality Forum would ultimately ensure that a said measure is up to par—so that’s the least of her concerns.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More